Zhigong Wei1,2,3, Zhengfang Zhang4, Jingwen Luo5, Nan Li5, Xingchen Peng6. 1. Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 2. The Affiliated Hospital of Northwest University and Xi'An No. 3 Hospital, Xi'An, 710016, Shaanxi, China. 3. Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 4. Department of Head and Neck, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 5. West China School of Medicine, Sichuan University, Chengdu, 610041, Sichuan, China. 6. Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. pxx2014@scu.edu.cn.
Abstract
BACKGROUND: To evaluate the value of concurrent chemotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiation therapy (IMRT), we performed this retrospective cohort study to compare the efficiency and toxicities of induction chemotherapy plus IMRT alone (IC + RT) versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy (IC + CCRT). METHOD: We analyzed data from patients with locoregionally advanced NPC (stage III-IVb) who were treated at the West China hospital between January 2008 and December 2014. Patients received docetaxel, cisplatin, and 5-fluorouracil (TPF) IC followed by IMRT alone (IC + RT group) or IMRT plus cisplatin concurrent chemotherapy (IC + CCRT group). The main endpoint was overall survival (OS), which was evaluated by the Kaplan-Meier method and log-rank test. Multivariate Cox proportional hazard analysis was used to identify potential independent prognostic factors. Treatment-associated toxicities were compared between groups using the Chi squared test. RESULTS: A total of 78 patients treated with IC + RT and 76 with IC + CCRT were analyzed. The median follow-up time was 59 months (range: 7-108 months). There was no difference between patients treated with IC + RT and IC + CCRT in terms of 3-year OS (89.0% versus 88.0%, p = 0.286), progression-free survival (76.8% versus 80.0%, p = 0.142), locoregional recurrence-free survival (87.1% versus 90.5%, p = 0.156), or distant metastasis-free survival (83.6% versus 82.6%, p = 0.567). Treatment (IC + RT versus IC + CCRT) was not an independent prognostic factor for OS (HR 1.425, 95% CI 0.698-2.908; p = 0.331). IC + CCRT was associated with a higher incidence of grade 3-4 neutropenia than IC + RT during radiotherapy (11.8% versus 1.3%, p = 0.020). CONCLUSION: IC plus IMRT alone achieves similar patient survival outcomes as IC plus IMRT-based concurrent chemoradiotherapy, and has a lower incidence of toxicity.
BACKGROUND: To evaluate the value of concurrent chemotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiation therapy (IMRT), we performed this retrospective cohort study to compare the efficiency and toxicities of induction chemotherapy plus IMRT alone (IC + RT) versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy (IC + CCRT). METHOD: We analyzed data from patients with locoregionally advanced NPC (stage III-IVb) who were treated at the West China hospital between January 2008 and December 2014. Patients received docetaxel, cisplatin, and 5-fluorouracil (TPF) IC followed by IMRT alone (IC + RT group) or IMRT plus cisplatin concurrent chemotherapy (IC + CCRT group). The main endpoint was overall survival (OS), which was evaluated by the Kaplan-Meier method and log-rank test. Multivariate Cox proportional hazard analysis was used to identify potential independent prognostic factors. Treatment-associated toxicities were compared between groups using the Chi squared test. RESULTS: A total of 78 patients treated with IC + RT and 76 with IC + CCRT were analyzed. The median follow-up time was 59 months (range: 7-108 months). There was no difference between patients treated with IC + RT and IC + CCRT in terms of 3-year OS (89.0% versus 88.0%, p = 0.286), progression-free survival (76.8% versus 80.0%, p = 0.142), locoregional recurrence-free survival (87.1% versus 90.5%, p = 0.156), or distant metastasis-free survival (83.6% versus 82.6%, p = 0.567). Treatment (IC + RT versus IC + CCRT) was not an independent prognostic factor for OS (HR 1.425, 95% CI 0.698-2.908; p = 0.331). IC + CCRT was associated with a higher incidence of grade 3-4 neutropenia than IC + RT during radiotherapy (11.8% versus 1.3%, p = 0.020). CONCLUSION: IC plus IMRT alone achieves similar patient survival outcomes as IC plus IMRT-based concurrent chemoradiotherapy, and has a lower incidence of toxicity.
Authors: Michael K M Kam; Peter M L Teo; Ricky M C Chau; K Y Cheung; Peter H K Choi; W H Kwan; S F Leung; Benny Zee; Anthony T C Chan Journal: Int J Radiat Oncol Biol Phys Date: 2004-12-01 Impact factor: 7.038
Authors: Ivan Weng-Keong Tham; Siew Wan Hee; Richard Ming-Chert Yeo; Patemah Bte Salleh; James Lee; Terence Wee-Kiat Tan; Kam Weng Fong; Eu Tiong Chua; Joseph Tien-Seng Wee Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-20 Impact factor: 7.038
Authors: Edwin P Hui; Brigette B Ma; Sing F Leung; Ann D King; Frankie Mo; Michael K Kam; Brian K Yu; Samuel K Chiu; Wing H Kwan; Rosalie Ho; Iris Chan; Anil T Ahuja; Benny C Zee; Anthony T Chan Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544